长期以来对卵巢交界性肿瘤(borderlineovariantumors,BOT)命名及病理诊断标准一直存在不同的意见。经过30余年的探索,对其本质认识逐步深入,特别是2003年8月在美国马里兰州贝塞斯达举行的卵巢交界性肿瘤工作会议,就卵巢交界性肿瘤的某些病理学方面的分歧取得了较一致的意见[1] There has been a long history of differing opinions on the naming and pathologic diagnosis of borderline ovariant tumors (BOT). After more than 30 years of exploration, the understanding of its essence has been gradually deepened. In particular, in August 2003, a meeting of ovarian borderline tumors held in Bethesda, Maryland, USA was conducted on some pathological differences in borderline ovarian tumors A more consistent opinion [1]